Cohance Lifesciences Files SEBI Reg 74(5) Certificate for Q4 FY26
Cohance Lifesciences Limited has submitted its quarterly certificate under SEBI Regulation 74(5) for the period ending March 31, 2026. This is a routine compliance filing confirming the dematerialization and rematerialization of securities.
This is a standard compliance filing related to share dematerialization and rematerialization, which is a routine process and typically has no material impact on the company's stock price or business operations.
The announcement is a routine regulatory compliance filing and does not contain any information that would positively or negatively impact the company's stock or operations.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The certificate confirms that details of securities dematerialized or rematerialized during the said period have been furnished to all the stock exchanges where the company's shares are listed. This confirmation was issued by KFin Technologies Limited, the company's Registrar and Share Transfer Agents, and has been provided to the BSE Limited and the National Stock Exchange of India Limited.
The submission is a routine compliance filing, ensuring adherence to SEBI regulations regarding the handling of securities. The company's Whole-time Director and Chief Financial Officer, Himanshu Agarwal, signed off on the disclosure. KFin Technologies Limited has also furnished the necessary details to the National Securities Depository Limited (NSDL) and the Central Depository Services (India) Ltd (CDSL).
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.